7-benzyloxy-1,3,4,5-tetrahydro-2H-2-benzazepin-1-one | 352356-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7-benzyloxy-1,3,4,5-tetrahydro-2H-2-benzazepin-1-one
• 英文别名: 7-phenylmethoxy-2,3,4,5-tetrahydro-2-benzazepin-1-one
• CAS: 352356-39-9
• 化学式: C₁₇H₁₇NO₂
• 分子量: 267.327
• InChiKey: LJYFXRMIPXJBLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-benzyloxy-1,3,4,5-tetrahydro-2H-2-benzazepin-1-one 在 10% palladium on activated carbon 、 氢气 、 sodium hydride 、 caesium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 23.0~80.0 ℃ 、101.33 kPa 条件下， 生成 ethyl 3-(7-(3-(methylamino)-2-nitrophenoxy)-1-oxo-1,3,4,5-tetrahydro-2H-benzo[c]azepin-2-yl)propanoate
  参考文献：
  名称：

  Synthesis and initial evaluation of novel, non-peptidic antagonists of the αv-integrins αvβ3 and αvβ5

  摘要：

  The discovery, synthesis and preliminary SAR of a novel class of non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5) is described. High-throughput screening of an extensive series of ECLiPS (TM) compound libraries led to the identification of compound 1 as a dual inhibitor of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). Optimization of compound 1 involving, in part, introduction of two novel constraints led to the discovery of compounds 15a and 15b with reduced PSA and much improved potency for both the alpha(v)beta(3) and alpha(v)beta(5) integrins. Compounds 15a and 15b were shown to have promising activity in functional cellular assays and compound 15a also exhibited a promising Caco-2 permeability profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.074
• 作为产物：
  描述：

  7-羟基-1,3,4,5-四氢-2H-2-苯并氮杂卓-1-酮 、 溴甲苯 在 sodium chloride 、 碳酸氢钠 、 potassium carbonate 作用下， 以 N-甲基乙酰胺 、 水 为溶剂， 生成 7-benzyloxy-1,3,4,5-tetrahydro-2H-2-benzazepin-1-one
  参考文献：
  名称：

  Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient

  摘要：

  式(I)1的苯融合杂环衍生物，其中所有符号与说明书中描述的相同，并其非毒性盐。式(I)的化合物对半胱氨酸蛋白酶具有抑制活性，因此可用作预防和/或治疗免疫疾病（自身免疫疾病、传染病等）、炎症性疾病（炎症性肠病、多发性硬化、关节炎等）、神经退行性疾病（阿尔茨海默病、肌营养不良等）、骨吸收疾病（骨质疏松症等）、呼吸系统疾病、糖尿病、休克等。

  公开号：

  US20030162964A1

文献信息

• [EN] OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)<br/>[FR] DÉRIVÉS D'OXADIAZOLE ACTIFS SUR LA SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：GLAXO GROUP LTD

  公开号：WO2009080725A1

  公开（公告）日：2009-07-02

  The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two substituents independently selected from halogen, C(1-3)aIkoxy, C(1-3)flyoroalkyl, cyano, optionally substituted phenyl. C(1-3)fluoroalkoxy. C(1-6)alkyl and C(3-6)Cyctoalkyl; R2 is hydrogen, halogen or C(1-4)alkyl; B is a 7 membered saturated ring selected from the following: Formulae (a) (b) (c) R3 is hydrogen or (CH2)1-4MCO2H; R4 is hydrogen or C(1-3)alkyl optionally interrupted by oxygen;

  本申请披露了一种基于噁二唑的化合物，其化学式为（I），对神经酰胺-1-磷脂酸（S1P）具有活性，特别适用于治疗红斑狼疮。其中，A为苯基或5或6元杂环芳基环；R1为最多两个取代基，可独立选择自卤素、C（1-3）烷氧基、C（1-3）氟烷基、氰基、可选择取代的苯基、C（1-3）氟烷氧基、C（1-6）烷基和C（3-6）环烷基；R2为氢、卤素或C（1-4）烷基；B为以下选项中的7元饱和环之一：（a）（b）（c）；R3为氢或（CH2）1-4MCO2H；R4为氢或C（1-3）烷基，可由氧原子中断。
• Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
  申请人：——

  公开号：US20030162964A1

  公开（公告）日：2003-08-28

  A benzene-fused heteroring derivative of formula (I) 1 , wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of immune diseases (autoimmune diseases, infectious diseases, etc.), inflammatory diseases (inflammatory bowel diseases, multiple cerebrosclerosis, arthritis, etc.), nerve degeneration diseases (Alzheimer's disease, muscular dystrophy, etc.), bone resorption diseases (osteoporosis, etc.), respiratory system diseases, diabetes, shock, etc.

  式(I)1的苯融合杂环衍生物，其中所有符号与说明书中描述的相同，并其非毒性盐。式(I)的化合物对半胱氨酸蛋白酶具有抑制活性，因此可用作预防和/或治疗免疫疾病（自身免疫疾病、传染病等）、炎症性疾病（炎症性肠病、多发性硬化、关节炎等）、神经退行性疾病（阿尔茨海默病、肌营养不良等）、骨吸收疾病（骨质疏松症等）、呼吸系统疾病、糖尿病、休克等。
• Synthesis of Novel Benzotriazoloazepine Derivatives
  作者：Wei Zhang、Rong-Bi Han、Wen-Bin Zhang、Ri-Shan Jiang、Feng-Yu Piao

  DOI：10.1002/jhet.961

  日期：2013.1

  from 7‐methoxy‐2,3,4,5‐tetrahydro‐1H‐2‐benzo[c]azepin‐1‐one. The compounds 2a–c have been synthesized by the reaction of 7‐methoxy‐2,3,4,5‐tetrahydro‐1H‐2‐benzo[c]azepin‐1‐thione with various hydrazides. Reaction of 5 with hydrazine hydrate, followed by treatment of the resultant hydrazone with formic acid, gave corresponding 9‐alkoxy‐6,7‐dihydro‐5H‐benzo[c][1,2,4]triazolo[4,3‐a]azepine(6a,b). Cyclization

  从7-甲氧基-2,3,4,5-四氢-1 H -2-苯并[c]氮杂-1-1开始合成了八种新的苯并三唑并a庚因衍生物。化合物2a-c是通过7-甲氧基-2,3,4,5-四氢-1 H -2-苯并[c] a嗪-1-硫酮与各种酰肼的反应合成的。5与水合肼反应，然后用甲酸处理所得，得到相应的9-烷氧基-6,7-二氢-5H-苯并[c] [1,2,4]三唑[4,3-a] ] azepine（6 a，b）。用氨基甲酸甲酯环化5，得到9-烷氧基-6,7-二氢-2H-苯并[c] [1,2,4]三唑[4,3-a] azepin-3（5H）-one（7 a– C）。通过其元素分析和光谱数据证实了化合物的结构。他们的抗惊厥活性已经过初步筛选。
• Synthesis and Anticonvulsant Activity of 9-Alkoxy-6,7-dihydro-2<i>H</i>-benzo[c][1,2,4]triazolo[4,3-a]azepin-3[5<i>H</i>]-ones
  作者：Feng-Yu Piao、Cheng-Xi Wei、Rong-Bi Han、Wen-Bin Zhang、Wei Zhang、Ri-Shan Jiang

  DOI：10.1080/00397911.2011.553762

  日期：2012.8.15

  Abstract A series of novel 9-alkoxy-6,7-dihydro-2H-benzo[c][1,2,4]triazolo[4,3-a]azepin-3(5H)-one derivatives was designed and synthesized starting from 2,3,4,5-tetrahydro-7-hydroxy-1H-2-benzazepin-1-one. The structures of these compounds were confirmed by mass, 1H NMR infrared spectra, and elemental analysis. Their anticonvulsant activity was evaluated by maximal electroshock (MES) test, and their

  摘要 设计并合成了一系列新型 9-烷氧基-6,7-二氢-2H-苯并[c][1,2,4]三唑并[4,3-a]azepin-3(5H)-one衍生物。来自 2,3,4,5-tetrahydro-7-hydroxy-1H-2-benzazepin-1-one。这些化合物的结构通过质量、1H NMR 红外光谱和元素分析得到证实。通过最大电休克 (MES) 试验评估其抗惊厥活性，并通过旋转棒神经毒性试验确定其神经毒性作用。结果表明，3k是活性最强的化合物，中位有效剂量（ED50）为27.3 mg/kg，中位毒性剂量（TD50）为118.3 mg/kg，保护指数（PI）为4.3。讨论了可能的构效关系。图形概要
• Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient
  申请人：Ohmoto Kazuyuki

  公开号：US20050009755A1

  公开（公告）日：2005-01-13

  A benzene-fused heteroring derivative of formula (I) wherein all symbols are the same as described in the specification, and a non-toxic salt thereof. The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of immune diseases (autoimmune diseases, infectious diseases, etc.), inflammatory diseases (inflammatory bowel diseases, multiple cerebrosclerosis, arthritis, etc.), nerve degeneration diseases (Alzheimer's disease, muscular dystrophy, etc.), bone resorption diseases (osteoporosis, etc.), respiratory system diseases, diabetes, shock, etc.

  式(I)的苯并杂环衍生物及其非毒性盐，其中所有符号与说明书中所述相同。式(I)化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗免疫疾病（自身免疫性疾病、传染病等）、炎症性疾病（炎症性肠病、多发性硬化症、关节炎等）、神经退行性疾病（阿尔茨海默病、肌萎缩症等）、骨吸收性疾病（骨质疏松症等）、呼吸系统疾病、糖尿病、休克等药剂。